Archive WILEX Press Releases

Selected press releases of the former years can be found here.

 2007

 2006

01 March 2006

WILEX Appoints Members to its Medical Advisory Board for RENCAREX®* and the Phase III ARISER Study

19 June 2006

Change in Senior Management of WILEX AG

31 July 2006

WILEX completes two Phase Ib studies with anti-cancer drug WX-UK1 in cancer patients

07 August 2006

WILEX completes Phase I program with anti-cancer drug WX-671 in healthy volunteers and holds clinical Phase Ib study in cancer patients now

11 October 2006

WILEX Plans IPO

16 October 2006

WILEX successfully completes Phase II study with RENCAREX®* in combination with Interferon

20 October 2006

New antibody based diagnostic imaging agent demonstrates 100 % positive predictive accuracy in feasibility study

24 October 2006

WILEX announces details of IPO

06 November 2006

Price range for WILEX shares set at EUR 13.80 to EUR 15.80

10 November 2006

WILEX shares successfully placed at EUR 13.80

13 December 2006

WILEX enters into manufacturing and distribution agreement with IBA Molecular for the upcoming pivotal registration trial with CA9-SCAN

15 December 2006

WILEX receives approval for clinical Phase II trial with oral WX-671 in pancreatic cancer

 2005

 2004

 2003

 2002 and earlier